Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

Slides:



Advertisements
Similar presentations
A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.
Advertisements

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Effects of SC144 on in vivo ovarian tumor.
NRP2 represses IGF-IR expression and signaling.
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.
In vivo efficacy of Olaparib in PTEN deficient xenografts.
Supplemental Figure 6 Supplemental Figure 6. Treatment with erlotinib plus TAS-115 inhibits the growth of PC-9/HGF tumors in vivo. (A, B) Nude mice bearing.
Effect of PV1(RIPO) on s.c.
Activity of MAC-321 (i. v. and p. o
IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.
Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.
Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.
Antitumor immunity caused by DS-8201a.
PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC
In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s
Effect of HA on hematopoietic recovery in tumor-bearing mice.
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.
NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,
Socially isolated SV40 Tag mice develop significantly larger mammary gland tumors. Socially isolated SV40 Tag mice develop significantly larger mammary.
In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.
Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
Matriptase-2 inhibited breast tumor development in vivo.
Induction of cell death in prostate cancer cells by SAHA and ZOL
Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.
Active AR signaling in enzalutamide-resistant xenograft tumors.
Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.
Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.
GA reduces the growth of Caki-1 tumor xenografts.
In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,
Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.
Antitumor effects of celastrol in vitro and in vivo.
MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.
Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Micrographs.
Xenograft regrowth studies.
Flow cytometric analysis of ROS production in oligonucleotide-treated PC3 prostate cancer cells as demonstrated by the oxidation of H2DCF → DCF and HE.
Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.
Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing BALB/c mice following VP-16 pretreatment. Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing.
Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.
A, tumor growth studies in H1975 tumor–bearing mice.
miR-100 suppresses bladder cancer cell growth in vitro and in vivo.
CRA inhibits the growth of human tumor xenografts in vivo.
NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.
A, inhibition of FGF2 binding to the FGFR by porphyrin analogues.
A and B, intratumoral DC-AdCCL21 leads to reduction in growth rates of bilateral tumors. A and B, intratumoral DC-AdCCL21 leads to reduction in growth.
Anti-SEMA4D antibody regulates immune-cell infiltration and inhibits growth of Tubo.A5 orthotopic mammary carcinoma. Anti-SEMA4D antibody regulates immune-cell.
Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.
Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.
Effect of dietary feeding of silibinin on DU145 tumor xenograft growth in athymic male nude mice. Effect of dietary feeding of silibinin on DU145 tumor.
Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.
Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.
SPARC is required for spontaneous metastasis
SW620 xenografts treated with combination siKRAS+siPIK3CA/B.
RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.
MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.
TAE-684 effectively inhibits the growth of H3122 in vivo.
Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.
Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.
PDL192 and inhibit the growth of xenograft tumors.
Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.
MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.
W. chinensis extract attenuates tumor growth of 103E (a subline of CWR22Rv1) engrafted in the prostate of nude mice. W. chinensis extract attenuates tumor.
Chemopreventive effect of bexarotene and budesonide on mouse SCLC
In vivo effect of KIN-193 on PTEN-deficient tumors.
DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.
Presentation transcript:

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. A549 human lung carcinoma (A), DU145 human prostate carcinoma (B), or PC3 human prostate carcinoma (C) tumors were established after the s.c. implantation of tumor cells into the flanks of athymic mice. Tumor-bearing mice were randomized into several groups when the tumors reached an average size of 105 mm3 (A549), 150 mm3 (DU145), or 150 mm3 (PC3). Daily oral administration of the crystal form or solid dispersion preparation was initiated on the day of randomization and continued for 2 wks (n = 5). Points, mean tumor volumes; bars, SE. Naoki Matsunaga et al. Mol Cancer Ther 2006;5:80-88 ©2006 by American Association for Cancer Research